Hematologic Malignancies - Siteman Cancer Center

More documents

Recommendations

Info

Hematologic MalignanciesClinical Trials (continued)Leukemia, Lymphoma, Myelomaand Stem Cell TransplantationPrimary CNSRTOG 0227PI: DavidMansurStudy Coordinator:Shannon RickeyPhase I/II Study of Pre-Irradiation Chemotherapy withMethotrexate, Rituximab, and Temozolomide and Post-Irradiation Temozolomide for Primary Central NervousSystem LymphomaAll Lymphoma Histologies08-0494 PI: Nancy L.BartlettStudy Coordinator:Justina FirstA Phase I/II Dose Escalation Study of the Pan-HistoneDeacetylase (HDAC) Inhibitor PCI-24781 in LymphomaNotes: Patients must have had no more than 4 prior therapies; priorallogeneic transplant not allowed.08-0543 PI: Nancy L.BartlettStudy Coordinator:Justina FirstA Phase I/IIa Open-Label Study of Pralatrexate and Gemcitabinewith Vitamin B12 and Folic Acid Supplementation in Patients withRelapsed or Refractory Lymphoproliferative MalignanciesNotes: Patients must have at least 1 prior treatment; no priorallogeneic transplant; patients must have relapsed > 100 days fromautologous transplant.T-Cell08-0170 PI: Nancy L.BartlettStudy Coordinator:Sarah LarsonA Phase I Dose Escalation Study of Weekly SGN-35 Alone andIn Combination with Gemcitabine in Patients with Relapsed/Refractory CD30-Positive Hematologic MalignanciesNotes: Patients with relapsed/refractory ALCL are eligible forthis trial.07-1079 PI: Nancy L.BartlettStudy Coordinator:Justina FirstA Phase 1, Open-Label Study of Pralatrexate with Vitamin B 12and Folic Acid Supplementation in Patients with Relapsed orRefractory Cutaneous T-Cell LymphomaNotes: Patients must have had at least 1 prior therapy. Patientswith mycosis fungoides and Sezary syndrome are eligible.08-0443 PI: Nancy L.BartlettStudy Coordinator:Justina FirstTreatment of Peripheral T-Cell Lymphoma with AggressiveInduction Chemotherapy Followed by Autologous Stem CellTransplant using Denileukin Diftitox (Ontak) for in-vivo Purgingand Post-Transplant Therapy: A Multicenter Phase II Clinical TrialNotes: For patients with previously untreated T-Cell Lymphoma orcould have received up to 1 prior cycle of chemotherapy07-0878 PI: Nancy L.BartlettStudy Coordinator:Rachael KeeleySingle Agent Phase II Study of Forodesine (BCX1777) in theTreatment of Cutaneous T-Cell LymphomaNotes: Patients must have progressed/recurred following 3 formsof systemic therapy, one of which must have been oral bexaratone(unless it was not tolerated or medically contraindicated). Patientsmust have stage IB-IVA CTCL; mycosis fungoides or Sezarysyndrome are eligible.HODGKIN LYMPHOMA (HL)08-0170 PI: Nancy L.BartlettStudy Coordinator:Sarah LarsonA Phase I Dose Escalation Study of Weekly SGN-35 Alone andin Combination with Gemcitabine in Patients with Relapsed/Refractory CD30-Positive Hematologic MalignanciesNotes: Patients with recurrent Hodgkin’s lymphoma must havefailed systemic therapy either as induction for advanced stagedisease or salvage therapy after initial radiotherapy for early stageand were ineligible for, refused treatment by or previously receivedstem cell transplant.07-0233 PI: Nancy L.BartlettStudy Coordinator:Sarah LarsonA Phase II Multicenter Study of Lenalidomide in Relapsed orRefractory Classical Hodgkin LymphomaNotes: Patients must have recurred after at least 1 prior therapy.Patients with any stage and who have had prior autologous orallogeneic stem cell transplant are eligible.CALGB 50602 PI: Nancy L.BartlettStudy Coordinator:Sarah LarsonA Phase II Study of Galiximab in Patients with Relapsed/Refractory Hodgkin’s LymphomaNotes: Patients must have had at least 2 prior treatments; priorautologous and/or allogeneic stem cell transplant is allowed.Chronic Lymphocytic Leukemia (CLL)CALGB 10404 PI: Nancy L.BartlettStudy Coordinator:Donna SeckfortA Randomized Phase II Study of Three Fludarabine/antibodyCombinations for Patients with Symptomatic, PreviouslyUntreated Chronic Lymphocytic LeukemiaNotes: For previously untreated CLL patients requiring therapy(symptomatic, intermediate or high-risk by Rai staging system).CALGB 10501 PI: Nancy L.BartlettStudy Coordinator:Donna SeckfortA Phase III Intergroup CLL Study of Asymptomatic Patients withUntreated Chronic Lymphocytic Leukemia Randomized to EarlyIntervention Versus Observation with Later Treatment in theHigh Risk Genetic Subset with IGV H Unmutated DiseaseNotes: For patients who are within 6 months of their initialdiagnosis, asymptomatic and low risk by Rai staging system.6
Multiple MyelomaCALGB 100104 PI: Ravi Vij Study Coordinator:Ryan MonahanA Phase III Randomized, Double-Blind Study of MaintenanceTherapy with CC-5013 or Placebo Following AutologousStem Cell Transplantation for Multiple MyelomaNotes: At least stage 1 MM, 2 months stable following therapy,no more than 12 months total prior therapy for MM.07-1136 PI: Ravi Vij Study Coordinator:Deborah GensburgPhase I/II Trial of combination CCI-779 (Temsirolimus) andBortezomib (VELCADE) in Relapsed and/or Relapsed/RefractoryMultiple Myeloma (MMRC CCI-779).Notes: Relapsed or relapsed/refractory Multiple Myeloma patients18 years old or greater with measurable disease.07-0775 PI: Ravi Vij Study Coordinator:Mark FialaAn Open-label, Single-arm, Phase 2 Study of Carfilzomib inPatients with Relapsed and Refractory Multiple MyelomaNotes: Ages 18 and older with a previous response with relapseand refractory to last line of therapy, must have been treated withbortezomib and either thalidomide or lenalidomide.07-0776 PI: Ravi Vij Study Coordinator:Mark FialaAn Open-label, Single-arm, Phase 2 Study of Carfilzomib inPatients with Relapsed Multiple MyelomaNotes: Ages 18 and older with a response to their prior line oftherapy.PDL PI: Ravi Vij Study Coordinator:Deborah GensburgA Phase 1b, Multicenter, Open-label, Dose-escalation Study ofHuLuc63 (Humanized Anti-CS1 Monoclonal IgG1 Antibody) inCombination with Lenalidomide and Dexamethasone in subjectswith Relapsed Multiple MyelomaGeneralTransplantCTN 0201 PI: John DiPersio Study Coordinator:Jeremy GabrielA Phase III Randomized, Multicenter Trial ComparingG-CSF Mobilized Peripheral Blood Stem Cell with MarrowTransplantation from HLA Compatible Unrelated DonorsNotes: AML, ALL, CML, MDS03-0349 PI: John DiPersio Study Coordinator:Sandra LopezA Phase I/II Study Evaluating The Safety And Efficacy OfAMD3100 For The Mobilization And Transplantation OfHLA-Matched Sibling Donor Hematopoietic Stem Cells InPatients With Advanced Hematological MalignanciesNotes: Patients age 18-70 with a 6/6 matched sibling donor.08-0011 PI: John DiPersio Study Coordinator:Liz ProcknowA Multicenter, Prospective Trial to Evaluate the Role of NKCell Kir Epitope Mismatch on Mortality and Disease Relapse inT-Cell Depleted Hematopoietic Stem Cell Transplantation fromHLA-C Mismatched, Unrelated Donors for Myeloid Malignancies(MT2004-04).GVHDCTN 0402 PI: John DiPersio Study Coordinator:Jeremy GabrielA Phase III Randomized, Multicenter Trial Comparing Sirolimus/Tacrolimus with Tacrolimus/Methotrexate as GVHD ProphylaxisAfter HLA-Matched, Related Peripheral Blood Stem CellTransplantation — BMT CTN 0402Notes: AML, ALL, CML, or MDS ages 2-60 with a performance statusof 70 and a 6/6 matched sib.08-0072 PI: PeterWesterveltStudy Coordinator:Jeremy GabrielA Phase III, Randomized, Double-Blind, Placebo-ControlledStudy to Evaluate the Efficacy and Safety of Prochymal (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells)Infusion in Combination with Corticosteroids for the Treatmentof newly diagnosed Acute GVHD.Supportive care03-1192 PI: John DiPersio Study Coordinator:Jeremy GabrielA Pilot Study Evaluating the Efficacy and Safety of the OralNeurokinin-1 Antagonist, Aprepitant, in Combination withOndansetron and Dexamethasone in Patients UndergoingAutologous Peripheral Blood Stem Cell TransplantationNotes: Patients age 18-70 with a diagnosis of Hodgkin’s Disease,Non-Hodgkin’s Lymphoma, Multiple Myeloma, and Amyloidosis.7
Page 2 and 3: Hematologic MalignanciesLeukemia, L
Page 4 and 5: Hematologic MalignanciesLeukemia, L

Hematologic Malignancies - Siteman Cancer Center

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?